Journal article
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
JJ McNeil, RL Woods, MR Nelson, AM Murray, CM Reid, B Kirpach, E Storey, RC Shah, RS Wolfe, AM Tonkin, AB Newman, JD Williamson, JE Lockery, KL Margolis, ME Ernst, WP Abhayaratna, N Stocks, SM Fitzgerald, RE Trevaks, SG Orchard Show all
Journals of Gerontology Series A Biological Sciences and Medical Sciences | OXFORD UNIV PRESS INC | Published : 2017
Abstract
Background There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Methods Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular di..
View full abstractGrants
Awarded by Minneapolis Medical Research Foundation
Funding Acknowledgements
The work was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (grant number U01AG029824); the National Health and Medical Research Council of Australia (grant numbers 334047 and 1127060); Monash University (Australia); the Victorian Cancer Agency (Australia).